On the morning of December 5, 2025, a Singapore-based professional consulting firm visited Chengdu West China Clinical Research Center Co., Ltd. (hereinafter referred to as “WCCR”). The two parties exchanged views on potential collaboration opportunities for overseas biomedical innovation projects to conduct clinical research in mainland China.
The meeting was attended by WCCR's General Manager Ms Niu Qian, heads of the Administration Department, CRC Department, CRO Department, and other business units. Ms Luo Wei, a representative from WCCR's parent organization, West China Precision Medicine Co., Ltd., and General Manager of West China Cell Therapy Research Institute Co., Ltd., was also invited to attend. During the meeting, each party introduced their respective service capabilities and resource networks, followed by in‑depth discussions on practical topics such as cross‑border clinical research processes, local implementation pathways, and technical collaboration models. The participants also focused on sharing experiences in CAR‑T and radiopharmaceutical development. Overseas biotech company representatives joined online and engaged in extensive interactive discussions with the on‑site participants.
This exchange is an important step for WCCR to connect with international R&D resources and build a cross‑border collaboration network. It aims to facilitate the effective alignment of overseas innovative technologies with domestic clinical resources and explore feasible pathways for industry‑academia‑research‑medical innovation and transformation. Looking ahead, WCCR will continue to steadily advance external exchanges and cooperation, continuously enhance its clinical research service capabilities and scope, and contribute to the high‑quality development of China’s pharmaceutical and health industry.
